Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses
D A Anthoney, Jay Naik, Iain RJ MacPherson, Donna Crawford, John M Hartley, Janet A Hartley, Tomohisa Saito, Masaichi Abe, Keith Jones, Masanori Miwa, Christopher Twelves* and TRJ Evans